article DiŠerential Gene Expression Induced by Two Genotoxic N-nitroso Carcinogens, Phenobarbital and Ethanol in Mouse Liver Examined with Oligonucleotide Microarray and Quantitative Real-time PCR

ofp21,Ccng1 and Snk was observed 28 days after administration; no other diŠerentially-expressed genes were evident. The present results suggest that DEN and DPN induce diŠerential gene expression in p53 target genes in liver within a few hours after administration and that these acute responses remained only partially in liver after 28 DNA recombination, DNA methylation, DNA transcription, apoptosis, cell cycle, extracelluar matrix protein, in‰ammation, dendritic cell, oncogene, tumor development, tumor growth factor, tumor suppressor, xenobiotic metabolism and signal transduction, and then added genes from our preliminary results of AŠymetrix GeneChip Mu74AV2.

[1]  G. Blandino,et al.  Mutant p53: an oncogenic transcription factor , 2007, Oncogene.

[2]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[3]  Meilan Jin,et al.  Gene Expression Analysis on the Dicyclanil-Induced Hepatocellular Tumors in Mice , 2006, Toxicologic pathology.

[4]  Alberto Inga,et al.  The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes , 2006, Molecular and Cellular Biology.

[5]  E. May,et al.  A comprehensive study of p53 transcriptional activity in thymus and spleen of γ irradiated mouse: High sensitivity of genes involved in the two main apoptotic pathways , 2006, International journal of radiation biology.

[6]  J. Weitzman,et al.  A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. , 2005, Cancer research.

[7]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[8]  R. Shippy,et al.  Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations , 2004, BMC Genomics.

[9]  Yumiko Sakai,et al.  Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. , 2004, Mutation research.

[10]  Z. Szallasi,et al.  Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. , 2004, Nucleic acids research.

[11]  A. Stromberg,et al.  Large-scale gene profiling of the liver in a mouse model of chronic, intragastric ethanol infusion. , 2004, Journal of hepatology.

[12]  Tomoyuki Shirai,et al.  Rapid analysis of gene expression changes caused by liver carcinogens and chemopreventive agents using a newly developed three‐dimensional microarray system , 2004, Cancer science.

[13]  J. Kang,et al.  Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. , 2003, Cancer genetics and cytogenetics.

[14]  Patricia A. Dyck,et al.  Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. , 2003, Carcinogenesis.

[15]  Marilyn J Aardema,et al.  Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. , 2002, Mutation research.

[16]  S. Tsuda,et al.  The Comet Assay with Multiple Mouse Organs: Comparison of Comet Assay Results and Carcinogenicity with 208 Chemicals Selected from the IARC Monographs and U.S. NTP Carcinogenicity Database** , 2000, Critical reviews in toxicology.

[17]  T. Hara,et al.  Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. , 1999, Mutation research.

[18]  T. Ito,et al.  Involvement of dendritic cell response to resistance of stomach carcinogenesis caused by N-methyl-N'-nitro-N-nitrosoguanidine in rats. , 1998, Cancer research.

[19]  K. Vousden,et al.  Characterisation of human cyclin G1 and G2: DNA damage inducible genes. , 1996, Oncogene.

[20]  T. Sofuni,et al.  Initial experiences and future directions for transgenic mouse mutation assays. , 1994, Mutation research.

[21]  H. Mori,et al.  Recommendations for the performance of UDS tests in vitro and in vivo. , 1994, Mutation research.

[22]  S. Mocellin,et al.  Complementary techniques: validation of gene expression data by quantitative real time PCR. , 2007, Advances in experimental medicine and biology.

[23]  C. Korgaonkar,et al.  Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. , 2003, Molecular cancer research : MCR.

[24]  R. Baan,et al.  DNA adducts, mutant frequencies, and mutation spectra in various organs of λlacZ mice exposed to ethylating agents , 1998, Environmental and molecular mutagenesis.